Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2024

Genmab — Maj 2024

Planlagt Fastgjort Låst Flyttet Genmab
540 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #499

    Let's hope the drug-developers will be as quick as the web-developers 😉

    1 Reply Last reply
    0
    • concilladoC Offline
      concilladoC Offline
      concillado
      wrote on sidst redigeret af
      #500

      😄

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #501

        Video: Den Europæiske Centralbank ECB sætter formentlig renten ned i næste uge, men hvor meget? Hør også om NVIDIA, Mærsk og DSV's interesse for at købe DB Schenker, samt om de to danske biotekselskaber Zealand Pharma, Novo Nordisk og Genmab. https://proinvestor.com/boards/120672

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #502

          In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States I did not realize cervical cancer was also still growing https://x.com/CACancerJournal/status/1795859675071529225

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #503

            Gentogen 18/4 15:54 er de forløbige data på Hexcd38 ikke godt på vej til at bevise at CDC spiller en stor rolle,altså modbevise denne artikkels påstand ?? Har Gmab iøvrigt udtalt sig om hex38 virkning i pts med høj exp af CD55 og CD59?

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #504

              Der fik jeg nok rodet jeg mig nok ud i noget :D, men den som ikke spørger lærer ikke noget.

              1 Reply Last reply
              0
              • L Offline
                L Offline
                lahn1
                wrote on sidst redigeret af
                #505

                Dem som ikke læste gentogens link så er det en spændende artikel om dara resistente patienter. https://portal.findresearcher.sdu.dk/en/publications/resistance-to-daratumumab-in-patients-with-multiple-myeloma

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #506

                  CancerNetwork®
                  @CancerNetwrk
                  .
                  @DrJulieVose
                  discusses her upcoming
                  @ASCO
                  presentation on epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 https://x.com/CancerNetwrk/status/1796134464667717885

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    ProinvestorNEWS
                    wrote on sidst redigeret af
                    #507

                    Kort video....
                    Pharma- og biotekopdatering uge 22 | Genmab, Zealand Pharma og Novo Nordisk https://proinvestor.com/boards/120686

                    1 Reply Last reply
                    0
                    • R Offline
                      R Offline
                      Raun
                      wrote on sidst redigeret af
                      #508

                      ASCO er noget atypisk for Genmab's kursudvikling i år..... I hvert fald de seneste år, har aktien i hvert fald steget pænt op imod ASCO, for efterfølgende at blive ramt af de ledeste tømmermænd i form af kursfald..... Tør vi håbe på at det bliver lige omvendt i år?.... For mit vedkommende er det en ren gyser 😮

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #509

                        Børsen gentager verdens 10 bedst sælgende lægemidler. 3. Ozempic 14 mia. USD, 10. Darzalex 9,7 mia. USD https://borsen.dk/nyheder/virksomheder/se-listen-novo-storsaellert-blandt-de-bedst-saelgende-i-verden?b_source=borsen&b_medium=row_0&b_campaign=list_1

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #510

                          Med hensyn til spørgsmålene i går om Hexa38, så er bedste kilde indtil videre vist nok statig artiklen fra the Lancet: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00228-1/fulltext

                          1 Reply Last reply
                          0
                          • StockBullS Offline
                            StockBullS Offline
                            StockBull
                            wrote on sidst redigeret af
                            #511

                            Der er en ny og meget interessant analyse af Genmab i Life Science ØU af David Mygind, som jeg varmt kan anbefale at undersøge nærmere. Efter at have læst analysen, føler jeg mig i hvert fald i meget bedre humør. Rigtig god weekend!

                            1 Reply Last reply
                            0
                            • N Offline
                              N Offline
                              NiklasZ
                              wrote on sidst redigeret af
                              #512

                              "
                              We’re advancing our DuoBody® platform technology with the goal to unlock the potential of #bispecific antibody research, as we work to transform how cancer is treated. Watch the video below to learn more about our technology. #ASCO24" https://x.com/Genmab/status/1796542979273809922?t=SBZtpWL3ba-xUGouEiqH3Q&s=19

                              1 Reply Last reply
                              0
                              • nohopeN Offline
                                nohopeN Offline
                                nohope
                                wrote on sidst redigeret af
                                #513

                                Jeg kan varmt anbefale at enhver analyse af GEN fra Myginds hånd tages med en pæn stor mængde brød til.

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #514

                                  Tak Gentogen, har leget lidt med AI og diskuteret CD38 resistent pts vs Hexabody-CD38 ved at fodre AI med artikler og forsøgsdata LOL 🙂 ja ja ved godt det nok ikke holder i virkeligheden. men her er hvad Chat GPT 4.0 siger om emnet i bullet points

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lahn1
                                    wrote on sidst redigeret af
                                    #515

                                    Based on the provided text and our previous discussions, there is strong evidence suggesting that Hexabody-CD38 should help Darzalex (DARA)-resistant patients. Here are the key points supporting this conclusion:

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #516

                                      Enhanced CDC: Hexabody-CD38 is engineered to enhance complement-dependent cytotoxicity (CDC) through hexamerization. This increased CDC activity can overcome the reduced sensitivity to complement-mediated lysis seen in DARA-resistant patients due to the upregulation of complement inhibitory proteins (CD55 and CD59).

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        lahn1
                                        wrote on sidst redigeret af
                                        #517

                                        Broader Mechanisms: Hexabody-CD38 not only enhances CDC but also maintains other mechanisms of action such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis induction. These multiple mechanisms provide a robust anti-tumor activity, which is beneficial for overcoming resistance

                                        1 Reply Last reply
                                        0
                                        • L Offline
                                          L Offline
                                          lahn1
                                          wrote on sidst redigeret af
                                          #518

                                          Effective in Lower CD38 Expression: The study shows that Hexabody-CD38 is effective even in cell lines with lower levels of CD38 expression, which is a common issue in DARA-resistant multiple myeloma (MM) patients.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper